엘레돈 파마슈티컬스(ELDN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.62 (-1.13%), 시가총액 $0.29B, 52주 최저~최고 $1.39 ~ $4.36.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. fo
엘레돈 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
엘레돈 파마슈티컬스의 현재 주가는 $2.62 (-1.13%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
엘레돈 파마슈티컬스의 시가총액은 약 $0.29B입니다.
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplan